PCI-32765 (ibrutinib)
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for PCI-32765 (ibrutinib), covering 2013-04-17 to 2015-03-13. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) [Phase 2]